Maier W, Zobel A: Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics. Eur Arch Psychiatry Clin Neurosci. 2008, 258 (Suppl 1): 12-20.
Article
PubMed
Google Scholar
Karasu TB, Gelenberg A, Merriam A, Wang P: American Psychiatric Association practice guideline for the treatment of patients with major depressive disorder. Am J Psychiatry. 2000, 157: 1-45.
Article
Google Scholar
Trivedi MH, Rush AJ, Wisniewski SR, et al: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry. 2006, 163: 28-40. 10.1176/appi.ajp.163.1.28.
Article
PubMed
Google Scholar
Serretti A, Zanardi AR, Rossini D, et al: Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry. 2001, 6: 586-592. 10.1038/sj.mp.4000876.
Article
CAS
PubMed
Google Scholar
Dempfle A, Scherag A, Hein R, et al: Gene-environment interactions for complex traits: Definitions, methodological requirements and challenges. Eur J Hum Genet. 2008, 16: 1164-1172. 10.1038/ejhg.2008.106.
Article
CAS
PubMed
Google Scholar
Angst J: Antidepressiver effect und genetische faktoren. Arzneimittelforschung. 1964, 14: 500-
Google Scholar
Pare CM, Rees L, Sainsbury MJ: Differentiation oftwo genetically specific types of depression by the response to antidepressants. Lancet. 1962, 2: 1340-1343.
Article
CAS
PubMed
Google Scholar
Pare CM, Mack JW: Differentiation of two genetically specific types of depression by the response to antidepressant drugs. J Med Genet. 1971, 8: 306-309. 10.1136/jmg.8.3.306.
Article
PubMed Central
CAS
PubMed
Google Scholar
O'Reilly RL, Bogue L, Singh SM: Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biol Psychiatry. 1994, 36: 467-471. 10.1016/0006-3223(94)90642-4.
Article
PubMed
Google Scholar
Franchini L, Serretti A, Gasperini M, Smeraldi E: Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res. 1998, 32: 255-259. 10.1016/S0022-3956(98)00004-1.
Article
CAS
PubMed
Google Scholar
Orsini A: Antidepressant responses and segregation analyses in affective families. Anxious Depression: Assessment and Treatment. Edited by: Racagni, G. and Smeraldi, E. 1987, Raven Press, New York, NY, USA
Google Scholar
Normann C, Horn M, Hummel B, et al: Paroxetine in major depression: Correlating plasma concentrations and clinical response. Pharmacopsychiatry. 2004, 37: 123-126.
Article
CAS
PubMed
Google Scholar
Drago A, De Ponti F, Boriani G, et al: Strategy for a genetic assessment of antipsychotic and antidepressant-related proarrhythmia. Curr Med Chem. 2008, 15: 2472-2517. 10.2174/092986708785909058.
Article
CAS
PubMed
Google Scholar
Peters EJ, Slager SL, Kraft JB, et al: Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS ONE. 2008, 3: e1872-10.1371/journal.pone.0001872.
Article
PubMed Central
PubMed
Google Scholar
Kato M, Fukuda T, Serretti A, et al: ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008, 32: 398-404. 10.1016/j.pnpbp.2007.09.003.
Article
CAS
PubMed
Google Scholar
Uhr M, Tontsch A, Namendorf C, et al: Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008, 57: 203-209. 10.1016/j.neuron.2007.11.017.
Article
CAS
PubMed
Google Scholar
David SP, Brown RA, Papandonatos GD, et al: Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res. 2007, 9: 821-833. 10.1080/14622200701382033.
Article
PubMed Central
CAS
PubMed
Google Scholar
Koski A, Sistonen J, Ojanpera I, et al: CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies. Forensic Sci Int. 2006, 158: 177-183. 10.1016/j.forsciint.2005.05.032.
Article
CAS
PubMed
Google Scholar
Shams ME, Arneth B, Hiemke C, et al: CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006, 31: 493-502. 10.1111/j.1365-2710.2006.00763.x.
Article
CAS
PubMed
Google Scholar
Suzuki Y, Sawamura K, Someya T: Polymorphisms in the 5-hydroxytryptamine 2A receptor and cytochrome P4502D6 genes synergistically predict fluvoxamine-induced side effects in Japanese depressed patients. Neuropsychopharmacology. 2006, 31: 825-831. 10.1038/sj.npp.1300919.
Article
CAS
PubMed
Google Scholar
Grasmader K, Verwohlt PL, Rietschel M, et al: Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol. 2004, 60: 329-336.
PubMed
Google Scholar
Rau T, Wohlleben G, Wuttke H, et al: CYP2D6 genotype: Impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther. 2004, 75: 386-393. 10.1016/j.clpt.2003.12.015.
Article
CAS
PubMed
Google Scholar
Roberts RL, Joyce PR, Mulder RT, et al: A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. 2002, 2: 191-196. 10.1038/sj.tpj.6500099.
Article
CAS
PubMed
Google Scholar
Hu J, Redden DT, Berrettini WH, et al: No evidence for a major role of polymorphisms during bupropion treatment. Obesity (Silver Spring). 2006, 14: 1863-1867. 10.1038/oby.2006.215.
Article
CAS
Google Scholar
Arias B, Serretti A, Lorenzi C, et al: Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Affect Disord. 2006, 90: 251-256. 10.1016/j.jad.2005.11.008.
Article
CAS
PubMed
Google Scholar
Szegedi A, Rujescu D, Tadic A, et al: The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J. 2005, 5: 49-53. 10.1038/sj.tpj.6500289.
Article
CAS
PubMed
Google Scholar
Moret C, Briley M: Serotonin autoreceptor subsensitivity and antidepressant activity. Eur J Pharmacol. 1990, 180: 351-356. 10.1016/0014-2999(90)90320-6.
Article
CAS
PubMed
Google Scholar
Meyer JH, Kapur S, Eisfeld B, et al: The effect of paroxetine on 5-HT(2A) receptors in depression: An [(18)F]setoperone PET imaging study. Am J Psychiatry. 2001, 158: 78-85. 10.1176/appi.ajp.158.1.78.
Article
CAS
PubMed
Google Scholar
Serretti A, Kato M, De Ronchi D, Kinoshita T: Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007, 12: 247-257.
CAS
PubMed
Google Scholar
Oberlander TF, Bonaguro RJ, Misri S, et al: Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry. 2008, 13: 65-73. 10.1038/sj.mp.4002007.
Article
CAS
PubMed
Google Scholar
Benedetti F, Barbini B, Bernasconi A, et al: Lithium overcomes the influence of 5-HTTLPR gene polymorphism on antidepressant response to sleep deprivation. J Clin Psychopharmacol. 2008, 28: 249-251. 10.1097/JCP.0b013e318167461e.
Article
PubMed
Google Scholar
Carli M, Reader TA: Regulation of central serotonin transporters by chronic lithium: An autoradiographic study. Synapse. 1997, 27: 83-89. 10.1002/(SICI)1098-2396(199709)27:1<83::AID-SYN9>3.0.CO;2-9.
Article
CAS
PubMed
Google Scholar
Perez V, Gilaberte I, Faries D, et al: Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 1997, 349: 1594-1597. 10.1016/S0140-6736(96)08007-5.
Article
CAS
PubMed
Google Scholar
Smeraldi E, Serretti A, Artioli P, et al: Serotonin transporter gene-linked polymorphic region: Possible pharmacogenetic implications of rare variants. Psychiatr Genet. 2006, 16: 153-158. 10.1097/01.ypg.0000218611.53064.a0.
Article
PubMed
Google Scholar
Hu XZ, Rush AJ, Charney D, et al: Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry. 2007, 64: 783-792. 10.1001/archpsyc.64.7.783.
Article
CAS
PubMed
Google Scholar
Kim DK, Lim SW, Lee S, et al: Serotonin transporter gene polymorphism and antidepressant response. Neuroreport. 2000, 11: 215-219. 10.1097/00001756-200001170-00042.
Article
CAS
PubMed
Google Scholar
Smits KM, Smits LJ, Peeters FP, et al: The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients. Psychiatr Genet. 2008, 18: 184-190. 10.1097/YPG.0b013e3283050aca.
Article
PubMed
Google Scholar
Drago A, De Ronchi D, Serretti A: 5-HT1A gene variants and psychiatric disorders: A review of current literature and selecttion of SNPs for future studies. Int J Neuropsychopharmacol. 2008, 11: 701-721.
Article
CAS
PubMed
Google Scholar
Serretti A, Drago A, De Ronchi D: HTR2A gene variants and psychiatric disorders: A review of current literature and selection of SNPs for future studies. Curr Med Chem. 2007, 14: 2053-2069.
Article
CAS
PubMed
Google Scholar
Pejchal T, Foley MA, Kosofsky BE, Waeber C: Chronic fluoxetine treatment selectively uncouples raphe 5-HT(1A) receptors as measured by [(35)S]-GTP gamma S autoradiography. Br J Pharmacol. 2002, 135: 1115-1122. 10.1038/sj.bjp.0704555.
Article
PubMed Central
CAS
PubMed
Google Scholar
Moulin-Sallanon M, Charnay Y, Ginovart N, et al: Acute and chronic effects of citalopram on 5-HT(1A) receptor-labeling by [(18)F]MPPF and -coupling to receptors-G proteins. Synapse. 2008, 63: 106-116. 10.1002/syn.20588.
Article
Google Scholar
Lemonde S, Turecki G, Bakish D, et al: Impaired trans-repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci. 2003, 23: 8788-8799.
CAS
PubMed
Google Scholar
Parsey RV, Olvet DM, Oquendo MA, et al: Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: Preliminary data from a naturalistic study. Neuropsychopharmacology. 2006, 31: 1745-1749. 10.1038/sj.npp.1300992.
Article
CAS
PubMed
Google Scholar
Levin GM, Bowles TM, Ehret MJ, et al: Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness. Mol Diagn Ther. 2007, 11: 155-160.
Article
CAS
PubMed
Google Scholar
Uher R: The implications of gene-environment interactions in depression: Will cause inform cure?. Mol Psychiatry. 2008, 13: 1070-1078. 10.1038/mp.2008.92.
Article
CAS
PubMed
Google Scholar
Arias B, Catalan R, Gasto C, et al: Evidence for a combined genetic effect of the 5-HT1A receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. J Psychopharmacol. 2005, 19: 166-172. 10.1177/0269881105049037.
Article
CAS
PubMed
Google Scholar
Sullivan PF: Spurious genetic associations. Biol Psychiatry. 2007, 61: 1121-1126. 10.1016/j.biopsych.2006.11.010.
Article
CAS
PubMed
Google Scholar
Peters EJ, Slager SL, McGrath PJ, et al: Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry. 2004, 9: 879-889. 10.1038/sj.mp.4001502.
Article
CAS
PubMed
Google Scholar
Spurlock G, Heils A, Holmans P, et al: A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol Psychiatry. 1998, 3: 42-49. 10.1038/sj.mp.4000342.
Article
CAS
PubMed
Google Scholar
Wilkie MJ, Smith G, Day RK, et al: Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J. 2009, 9: 61-70. 10.1038/sj.tpj.6500491.
Article
CAS
PubMed
Google Scholar
Tanaka M, Kobayashi D, Murakami Y, et al: Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. Int J Neuropsychopharmacol. 2008, 11: 261-267.
Article
CAS
PubMed
Google Scholar
Stahl S: 5HT1A receptors and pharmacotherapy. Is serotonin receptor down-regulation linked to the mechanism of action of antidepressant drugs?. Psychopharmacol Bull. 1994, 30: 39-43.
CAS
PubMed
Google Scholar
Nakamura K, Sugawara Y, Sawabe K, et al: Late developmental stage-specific role of tryptophan hydroxylase 1 in brain serotonin levels. J Neurosci. 2006, 26: 530-534. 10.1523/JNEUROSCI.1835-05.2006.
Article
CAS
PubMed
Google Scholar
Jonsson EG, Goldman D, Spurlock G, et al: Tryptophan hydroxylase and catechol-O-methyltransferase gene polymorphisms: Relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Eur Arch Psychiatr Clin Neurosci. 1997, 247: 297-302. 10.1007/BF02922258.
Article
CAS
Google Scholar
Ham BJ, Lee BC, Paik JW, et al: Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population. Prog Neuropsychopharmacol Biol Psychiatry. 2007, 31: 104-107. 10.1016/j.pnpbp.2006.08.001.
Article
CAS
PubMed
Google Scholar
Ham B, Lee M, Lee H, et al: No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population. Psychiatr Genet. 2005, 15: 229-301. 10.1097/00041444-200509000-00016.
Article
Google Scholar
Serretti A, Cusin C, Rossini D, et al: Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am J Med Genet B Neuropsychiatr Genet. 2004, 129: 36-40.
Article
Google Scholar
Serretti A, Zanardi R, Cusin C, et al: Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur Neuropsychopharmacol. 2001, 11: 375-380. 10.1016/S0924-977X(01)00113-4.
Article
CAS
PubMed
Google Scholar
Serretti A, Cristina S, Lilli R, et al: Family-based association study of 5-HTTLPR, TPH, MAO-A, and DRD4 polymorphisms in mood disorders. Am J Med Genet. 2002, 114: 361-369. 10.1002/ajmg.10356.
Article
PubMed
Google Scholar
Cusin C, Serretti A, Zanardi R, et al: Influence of monoamine oxydase A and serotonin receptor 2A polymorphisms in SSRIs antidepressant activity. Int J Neuropsychopharmacol. 2002, 5: 27-35.
Article
CAS
PubMed
Google Scholar
Lotrich FE, Pollock BG, Kirshner M, et al: Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients. J Psychiatry Neurosci. 2008, 33: 123-130.
PubMed Central
PubMed
Google Scholar
Kirchheiner J, Nickchen K, Sasse J, et al: A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogenomics J. 2007, 7: 48-55. 10.1038/sj.tpj.6500398.
Article
CAS
PubMed
Google Scholar
Kim H, Lim SW, Kim S, et al: Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA. 2006, 296: 1609-1618. 10.1001/jama.296.13.1609.
Article
CAS
PubMed
Google Scholar
Popp J, Leucht S, Heres S, Steimer W: Serotonin transporter polymorphisms and side effects in antidepressant therapy -- A pilot study. Pharmacogenomics. 2006, 7: 159-166. 10.2217/14622416.7.2.159.
Article
CAS
PubMed
Google Scholar
Hong CJ, Chen TJ, Yu YW, Tsai SJ: Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J. 2006, 6: 27-33. 10.1038/sj.tpj.6500340.
Article
CAS
PubMed
Google Scholar
Kato M, Fukuda T, Wakeno M, et al: Effects ofthe serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology. 2006, 53: 186-195. 10.1159/000094727.
Article
CAS
PubMed
Google Scholar
Serretti A, Zanardi R, Franchini L, et al: Pharmacogenetics ofselective serotonin reuptake inhibitor response: A 6-month follow-up. Pharmacogenetics. 2004, 14: 607-613. 10.1097/00008571-200409000-00005.
Article
CAS
PubMed
Google Scholar
Yoshida K, Takahashi H, Higuchi H, et al: Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry. 2004, 161: 1575-1580. 10.1176/appi.ajp.161.9.1575.
Article
PubMed
Google Scholar
Lee MS, Lee HY, Lee HJ, Ryu SH: Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatr Genet. 2004, 14: 111-115. 10.1097/01.ypg.0000107928.32051.11.
Article
PubMed
Google Scholar
Durham LK, Webb SM, Milos PM, et al: The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Bert). 2004, 174: 525-529.
CAS
Google Scholar
Arias B, Catalan R, Gasto C, et al: 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol. 2003, 23: 563-567. 10.1097/01.jcp.0000095350.32154.73.
Article
CAS
PubMed
Google Scholar
Joyce PR, Mulder RT, Luty SE, et al: Age-dependent antidepressant pharmacogenomics: Polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol. 2003, 6: 339-346. 10.1017/S1461145703003663.
Article
CAS
PubMed
Google Scholar
Yu YW, Tsai SJ, Chen TJ, et al: Association studyofthe serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry. 2002, 7: 1115-1119. 10.1038/sj.mp.4001141.
Article
CAS
PubMed
Google Scholar
Zanardi R, Serretti A, Rossini D, et al: Factors affecting fluvoxamine antidepressant activity: Influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry. 2001, 50: 323-330. 10.1016/S0006-3223(01)01118-0.
Article
CAS
PubMed
Google Scholar
Mundo E, Walker M, Cate T, et al: The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder. Arch Gen Psychiatry. 2001, 58: 539-544. 10.1001/archpsyc.58.6.539.
Article
CAS
PubMed
Google Scholar
Minov C, Baghai TC, Schule C, et al: Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett. 2001, 303: 119-122. 10.1016/S0304-3940(01)01704-9.
Article
CAS
PubMed
Google Scholar
Shishkina GT, Kalinina TS, Dygalo NN: Up-regulation of tryptophan hydroxylase-2 mRNA in the rat brain by chronic fluoxetine treatment correlates with its antidepressant effect. Neuroscience. 2007, 150: 404-412. 10.1016/j.neuroscience.2007.09.017.
Article
CAS
PubMed
Google Scholar
Siffert W, Rosskopf D, Siffert G, et al: Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet. 1998, 18: 45-48. 10.1038/ng0198-45.
Article
CAS
PubMed
Google Scholar
Holsboer F: The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 2000, 23: 477-501. 10.1016/S0893-133X(00)00159-7.
Article
CAS
PubMed
Google Scholar
Binder E, Salyakina D, Lichtner P, et al: Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet. 2004, 36: 1319-1325. 10.1038/ng1479.
Article
CAS
PubMed
Google Scholar
Tsai SJ, Hong CJ, Chen TJ, Yu YW: Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment. Am J Med Genet B Neuropsychiatr Genet. 2007, 144B: 1097-1098. 10.1002/ajmg.b.30246.
Article
CAS
PubMed
Google Scholar
Liu Z, Zhu F, Wang G, et al: Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett. 2007, 414: 155-158. 10.1016/j.neulet.2006.12.013.
Article
CAS
PubMed
Google Scholar
Egan MF, Kojima M, Callicott JH, et al: The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003, 112: 257-269. 10.1016/S0092-8674(03)00035-7.
Article
CAS
PubMed
Google Scholar
Gratacos M, Soria V, Urretavizcaya M, et al: A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Pharmacogenomics J. 2008, 8: 101-112. 10.1038/sj.tpj.6500460.
Article
CAS
PubMed
Google Scholar
Hall D, Dhilla A, Charalambous A, et al: Sequence variants of the brain-derived neurotrophic factor (BDNF) gene are strongly associated with obsessive-compulsive disorder. Am J Hum Genet. 2003, 73: 370-376. 10.1086/377003.
Article
PubMed Central
CAS
PubMed
Google Scholar
Hunnerkopf R, Strobel A, Gutknecht L, et al: Interaction between BDNF Val66Met and dopamine transporter gene variation influences anxiety-related traits. Neuropsychopharmacology. 2007, 32: 2552-2560. 10.1038/sj.npp.1301383.
Article
PubMed
Google Scholar
Ribases M, Gratacos M, Armengol L, et al: Met66 in the brain-derived neurotrophic factor (BDNF) precursor is associated with anorexia nervosa restrictive type. Mol Psychiatry. 2003, 8: 745-751. 10.1038/sj.mp.4001281.
Article
CAS
PubMed
Google Scholar
Serretti A, Artioli P, Lorenzi C, et al: The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: Preliminary findings. Int J Neuropsychopharmacol. 2004, 7: 453-460. 10.1017/S1461145704004687.
Article
CAS
PubMed
Google Scholar
Yu YW, Tsai SJ, Liou YJ, et al: Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur Neuropsychopharmacol. 2006, 16: 498-503. 10.1016/j.euroneuro.2005.12.004.
Article
CAS
PubMed
Google Scholar
McMahon FJ, Buervenich S, Charney D, et al: Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006, 78: 804-814. 10.1086/503820.
Article
PubMed Central
CAS
PubMed
Google Scholar
Murphy G, Hollander S, Rodrigues H, Schatzberg A: Effects of the serotonin transporter promoter polymorphism on paroxetine and mirtazapine efficacy and side effects in geriatric major depression. Pharmacogenetics in Psychiatry Meeting. Edited by: Hospital, T.Z.H. 2003, New York, NY, p. green tab., 1:
Google Scholar
Rosa A, Cuesta MJ, Fatjo-Vilas M, et al: The Val66Met polymorphism of the brain-derived neurotrophic factor gene is associated with risk for psychosis: Evidence from a family-based association study. Am J Med Genet B Neuropsychiatr Genet. 2006, 141B: 135-138. 10.1002/ajmg.b.30266.
Article
PubMed
Google Scholar
Nebert DW, Zhang G, Vesell ES: From human genetics and genomics to pharmacogenetics and pharmacogenomics: Past lessons, future directions. Drug Metab Rev. 2008, 40: 187-224. 10.1080/03602530801952864.
Article
PubMed Central
CAS
PubMed
Google Scholar
Serretti A, Kato M, Kennedy LJ: Pharmacogenetic studies in depression: A proposal for methodologic guidelines. Pharmacogenomics J. 2008, 8: 90-100. 10.1038/sj.tpj.6500477.
Article
CAS
PubMed
Google Scholar
Nebert DW: Suggestions for the nomenclature of human alleles: Relevance to ecogenetics, pharmacogenetics and molecular epidemiology. Pharmacogenetics. 2000, 10: 279-290. 10.1097/00008571-200006000-00001.
Article
CAS
PubMed
Google Scholar
Gerstein MB, Bruce C, Rozowsky JS, et al: What is a gene, post-ENCODE? History and updated definition. Genome Res. 2007, 17: 669-681. 10.1101/gr.6339607.
Article
CAS
PubMed
Google Scholar